Does EmblemHealth Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo is an anabolic agent, not an antiresorptive. That single distinction drives the entire insurance-approval process. While bisphosphonates such as alendronate suppress bone breakdown, teriparatide actively stimulates new bone formation by activating PTH receptor 1 on osteoblasts. The FDA approved Forteo in 2002 for postmenopausal women at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis [1].

The key Fracture Prevention Trial (N=1,637 postmenopausal women) demonstrated that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fragility fractures by 53% compared with placebo over a median of 19 months [2]. Those numbers explain why clinicians pursue coverage even when the prior-authorization process is demanding.

Teriparatide carries a boxed warning for osteosarcoma risk based on rat studies, which is why the FDA restricts its use to a maximum of two cumulative years per lifetime and why EmblemHealth's clinical criteria echo that restriction [1]. Patients with Paget's disease, prior radiation to the skeleton, or existing hypercalcemia are excluded.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines position teriparatide as a first-choice agent in patients with very high fracture risk, defined as a T-score below -3.0, multiple vertebral fractures, or a prior hip fracture [3]. That guideline language matters: insurers including EmblemHealth frequently cite it when deciding whether a patient qualifies to bypass step therapy.

How EmblemHealth's Pharmacy Benefit Tiers Work

EmblemHealth places most branded specialty drugs on Tier 4 or Tier 5 of its pharmacy formulary. Forteo sits in that range across its commercial HMO, PPO, and Medicare Advantage products. Tier placement determines your cost-sharing structure before any assistance is applied.

Under most EmblemHealth commercial plans, Tier 4 specialty drugs carry a coinsurance rate of 20 to 40% after the deductible is met, rather than a fixed copay. On a $3,200 monthly drug cost, 30% coinsurance equals $960 per fill. Under Medicare Advantage plans that include a Part D drug benefit, cost-sharing follows the standard catastrophic coverage phases, which in 2025 cap out-of-pocket drug spending at $2,000 annually under the Inflation Reduction Act changes [4].

EmblemHealth administers specialty pharmacy benefits through a designated specialty pharmacy network. Forteo must typically be dispensed by an in-network specialty pharmacy, and the prescriber submits the prior authorization through the EmblemHealth provider portal or by fax. Processing time is typically 3, 5 business days for a standard review and 24 to 72 hours for an expedited review when the prescriber documents urgent clinical need.

What Are EmblemHealth's Prior Authorization Criteria for Forteo?

Prior authorization approval for Forteo under EmblemHealth requires meeting specific clinical thresholds. Missing even one of them is the most common reason for initial denial.

EmblemHealth's published clinical criteria for teriparatide generally require all of the following:

Diagnosis of osteoporosis confirmed by DXA. The member must have a bone mineral density T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, or a T-score of -1.0 to -2.5 with a documented fragility fracture (osteopenia-plus-fracture classification).

High or very high fracture risk. A FRAX score (10-year probability of major osteoporotic fracture) at or above 20%, or a 10-year hip fracture probability at or above 3%, satisfies most EmblemHealth plans. A prior low-trauma vertebral or hip fracture alone typically qualifies without a FRAX calculation.

Step therapy: prior bisphosphonate trial. Most EmblemHealth commercial plans require a documented trial of at least 6 months with an oral bisphosphonate (alendronate, risedronate) or 12 months with zoledronic acid 5 mg IV, unless the prescriber documents a clinical reason for exemption. Accepted exemptions include documented bisphosphonate-related osteonecrosis of the jaw, atypical femur fracture, severe esophageal dysmotility, or renal insufficiency with GFR <35 mL/min.

Prescriber specialty. Some EmblemHealth plans require or strongly prefer that Forteo be prescribed by an endocrinologist, rheumatologist, or orthopedic specialist rather than a primary care physician, though this is not universal across all plan types.

Two-year lifetime limit. EmblemHealth will not authorize teriparatide for more than two cumulative years. If a patient previously received a full course, re-authorization is generally not available regardless of fracture history.

The following decision framework summarizes the EmblemHealth Forteo approval path for clinicians:

1. Obtain DXA confirming T-score <-2.5 or T-score <-1.0 with fragility fracture.
2. Calculate FRAX score and document 10-year probabilities in the chart.
3. Document bisphosphonate trial outcome (failure, intolerance, or contraindication).
4. Identify prescribing specialist or document why specialist referral was not feasible.
5. Submit PA with DEXA report, FRAX printout, fracture imaging if applicable, and clinical notes documenting bisphosphonate history.
6. Request expedited review if the patient has an acute vertebral fracture or is at imminent fracture risk per AACE criteria [3].

What Happens if EmblemHealth Denies Forteo Coverage?

A denial is not the end of the road. EmblemHealth, like all ACA-compliant and CMS-regulated plans, must provide a formal denial notice with a specific reason and instructions for appeal. Two appeal levels are available internally (first-level appeal, then second-level or external independent review).

The most effective appeals include a detailed letter of medical necessity from the treating physician, peer-reviewed literature supporting teriparatide over antiresorptives in the patient's specific clinical scenario, and documentation of why continued bisphosphonate therapy is not appropriate. The AACE 2020 position statement stating that "patients with very high fracture risk may appropriately receive anabolic therapy as initial treatment" is particularly useful as a supporting quotation in appeal letters [3].

External independent review is available if the internal appeal is denied. Under New York State insurance law (which governs most EmblemHealth commercial plans), external review must be completed within 45 days for standard requests and 72 hours for expedited requests. The independent organization's decision is binding on EmblemHealth.

A study published in JAMA Internal Medicine found that patients who appealed specialty drug denials succeeded approximately 39% of the time at the first internal appeal level [5]. Persistence matters. Submitting an appeal with complete documentation on the first attempt substantially improves those odds.

Biosimilar Alternative: Bonsity (Teriparatide-tpvr)

Bonsity, manufactured by Alvogen/Teva, received FDA approval in June 2019 as the first biosimilar to Forteo [6]. It delivers the same 20 mcg/day dose of teriparatide via a similar prefilled pen device. EmblemHealth formularies in some plan types list Bonsity at a lower tier than brand Forteo, which could reduce cost-sharing by 15 to 25%.

Clinically, biosimilar teriparatide is pharmacokinetically equivalent to Forteo. The FDA reviewed comparative pharmacokinetic, pharmacodynamic, and structural data before approving Bonsity, confirming no clinically meaningful differences in absorption, peak serum concentration, or bone turnover marker response [6]. The boxed warning, contraindications, and two-year lifetime limit apply identically.

Prescribers who anticipate EmblemHealth pushback on Forteo may find it worth requesting a formulary comparison from EmblemHealth's member services (1-800-624-2414) to determine whether Bonsity carries lower cost-sharing or a less stringent prior authorization pathway in the member's specific plan year.

Romosozumab and Denosumab: When EmblemHealth May Cover Alternatives First

If Forteo is denied and the patient genuinely needs an anabolic or high-potency agent, two other drugs enter the conversation.

Romosozumab (Evenity, 210 mg SC monthly for 12 doses) is FDA-approved for postmenopausal women with osteoporosis at high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fractures by 27% versus alendronate alone at 24 months [7]. Romosozumab carries a boxed warning for myocardial infarction, stroke, and cardiovascular death and is contraindicated within 12 months of a cardiac event. EmblemHealth's PA criteria for Evenity are similar in structure to those for Forteo but may differ in step therapy requirements.

Denosumab (Prolia, 60 mg SC every 6 months) is an antiresorptive, not anabolic, so it is pharmacologically different from teriparatide. EmblemHealth typically places Prolia on a lower specialty tier than Forteo, and prior authorization criteria are less demanding. For patients who cannot obtain Forteo authorization, denosumab produces meaningful vertebral fracture risk reduction and may be an appropriate bridge or alternative [8].

A rheumatologist or endocrinologist familiar with EmblemHealth's medical policy updates can help identify which pathway is most likely to succeed in a given plan year, since formulary positioning changes at each January 1 renewal.

Cost Assistance Programs That Work Alongside EmblemHealth Coverage

Even with EmblemHealth coverage in place, specialty cost-sharing can be substantial. Three programs apply to most commercially insured patients.

Eli Lilly's Forteo Savings Card reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients (not available for Medicare or Medicaid). Eligibility is confirmed at LillyCares.com or via the patient's specialty pharmacy.

Lilly Cares Foundation Patient Assistance Program provides Forteo at no cost to uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. Applications are completed by the prescriber.

State Pharmaceutical Assistance Programs (SPAPs) in New York (EPIC program) and Connecticut (CONNPACE) may provide additional cost-sharing relief for Medicare-enrolled EmblemHealth members who exhaust the manufacturer program.

Patients on Medicare Advantage should not use manufacturer copay cards (CMS prohibits this), but the $2,000 out-of-pocket cap enacted for 2025 under the Inflation Reduction Act provides meaningful protection for those reaching catastrophic coverage [4]. The Medicare Extra Help program (Low Income Subsidy) reduces Part D cost-sharing further for qualifying beneficiaries.

How to Work With Your Doctor to Maximize Approval Odds

Getting Forteo covered by EmblemHealth is primarily a documentation exercise. Clinicians who submit complete, well-organized prior authorization packages on the first attempt achieve faster approvals and fewer denials.

Start the process at least 4 weeks before the intended start date. Request a current EmblemHealth formulary and benefit summary from member services or the provider portal before submitting, because clinical criteria are updated annually. Confirm whether your plan requires specialty pharmacy dispensing and, if so, which pharmacies are in-network.

Your prescriber should include in the prior authorization submission: the DXA report with T-scores, the FRAX calculator output, imaging reports for any fractures, a detailed medication history documenting bisphosphonate use and reason for discontinuation or non-use, and a letter of medical necessity that directly maps each EmblemHealth criterion to documented evidence in the chart.

The National Osteoporosis Foundation (now operating under the Bone Health and Osteoporosis Foundation) recommends initiating pharmacologic treatment in postmenopausal women and men age 50 or older who have a hip or vertebral fracture, a T-score of -2.5 or lower, or a T-score between -1.0 and -2.5 with a 10-year FRAX probability meeting intervention thresholds [9]. Citing this recommendation in the medical necessity letter contextualizes the clinical urgency for the EmblemHealth medical reviewer.

If the prescriber is a primary care physician and EmblemHealth's criteria suggest specialist involvement, a co-signature or consultation note from an endocrinologist or rheumatologist can prevent a denial on that basis alone.

What Patients Should Know Before Their First Injection

Forteo requires daily subcutaneous self-injection using a prefilled pen device. The pen contains a 28-day supply (28 doses of 20 mcg). It must be refrigerated at 36, 46 degrees Fahrenheit and discarded 28 days after first use even if doses remain.

Common adverse effects include nausea (8.5% vs. 3.4% placebo in the Fracture Prevention Trial), leg cramps (2.6% vs. 1.3%), and transient orthostatic hypotension, particularly after the first few doses [2]. Patients should sit or lie down for the first few injections to monitor for dizziness. Serum calcium should be checked before starting, since teriparatide modestly raises serum calcium and is contraindicated in pre-existing hypercalcemia.

Patients who complete a two-year course should transition to an antiresorptive agent immediately after stopping. The DATA-Switch trial showed that transitioning from teriparatide to denosumab 60 mg produced continued BMD gains of approximately 6.6% at the lumbar spine over the following 24 months [10]. Stopping teriparatide without a sequential antiresorptive leads to rapid bone loss within 12 months.

EmblemHealth's specialty pharmacy typically ships a 30-day supply at a time with auto-refill available. Confirm shipping address and refrigeration arrangements at the pharmacy before the first shipment.